About the Report
Cancer treatments have been advancing at an accelerated pace in recent years, offering notable improvements in clinical benefit to patients. This report highlights advances in cancer therapeutics, including the use of these drugs and their global spending trends, the pipeline of therapeutic innovation and associated clinical trial activity, and the outlook through 2022. The report aims to provide an evidence base that can be used in discussion about the broader implications for cancer patients and their families, providers and their institutions, public and private payers at the local and national level, as well as multinational organizations.
The number of approved cancer therapies continues to rise, with 63 cancer drugs launching within the past five years. The continued rise and impact of immuno-oncology has been largely centered on the PD-1 and PD-L1 checkpoint inhibitors, which have broad efficacy across solid tumors and are used across 23 different tumor types. Of the 14 New Active Substance cancer therapeutics launched in 2017 alone, all of them were targeted therapies and 11 of them were granted Breakthrough Therapy designations by the FDA.